Daniela Graham

1.2k total citations · 1 hit paper
22 papers, 871 citations indexed

About

Daniela Graham is a scholar working on Rheumatology, Immunology and Dermatology. According to data from OpenAlex, Daniela Graham has authored 22 papers receiving a total of 871 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Rheumatology, 10 papers in Immunology and 5 papers in Dermatology. Recurrent topics in Daniela Graham's work include Spondyloarthritis Studies and Treatments (10 papers), Rheumatoid Arthritis Research and Therapies (10 papers) and Psoriasis: Treatment and Pathogenesis (5 papers). Daniela Graham is often cited by papers focused on Spondyloarthritis Studies and Treatments (10 papers), Rheumatoid Arthritis Research and Therapies (10 papers) and Psoriasis: Treatment and Pathogenesis (5 papers). Daniela Graham collaborates with scholars based in United States, Australia and Canada. Daniela Graham's co-authors include Cunshan Wang, Philip J. Mease, Keith S. Kanik, Thijs Hendrikx, Désirée van der Heijde, Oliver FitzGerald, Stephen Hall, Joseph F. Merola, Francisco Ávila‐Zapata and Sujatha Menon and has published in prestigious journals such as New England Journal of Medicine, PEDIATRICS and Annals of the Rheumatic Diseases.

In The Last Decade

Daniela Graham

21 papers receiving 853 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis

2017 421 citations Philip J. Mease, Stephen Hall et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniela Graham United States	9	552	442	313	128	107	22	871
Naonobu Sugiyama Japan	14	480 0.9×	359 0.8×	195 0.6×	111 0.9×	50 0.5×	34	871
Zuhre Tutuncu United States	10	821 1.5×	585 1.3×	378 1.2×	33 0.3×	36 0.3×	15	1.1k
Myrna Cardiel United States	3	539 1.0×	162 0.4×	304 1.0×	157 1.2×	40 0.4×	5	711
J.M. Kremer United States	10	551 1.0×	194 0.4×	269 0.9×	54 0.4×	58 0.5×	27	798
Chiara Bazzani Italy	17	559 1.0×	240 0.5×	186 0.6×	31 0.2×	43 0.4×	38	840
Jeffrey Neal United States	6	614 1.1×	353 0.8×	317 1.0×	92 0.7×	56 0.5×	9	866
Peter Noertersheuser United States	10	165 0.3×	181 0.4×	118 0.4×	63 0.5×	79 0.7×	22	626
Ivana Vranić United Kingdom	12	351 0.6×	296 0.7×	153 0.5×	208 1.6×	551 5.1×	30	1.2k
Christina Dickson United States	10	701 1.3×	221 0.5×	276 0.9×	236 1.8×	25 0.2×	13	931
K. D. Watson United Kingdom	3	519 0.9×	244 0.6×	160 0.5×	58 0.5×	27 0.3×	3	724

Countries citing papers authored by Daniela Graham

Since Specialization

Citations

This map shows the geographic impact of Daniela Graham's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniela Graham with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniela Graham more than expected).

Fields of papers citing papers by Daniela Graham

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniela Graham. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniela Graham. The network helps show where Daniela Graham may publish in the future.

Co-authorship network of co-authors of Daniela Graham

This figure shows the co-authorship network connecting the top 25 collaborators of Daniela Graham. A scholar is included among the top collaborators of Daniela Graham based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniela Graham. Daniela Graham is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Barnes, David M., et al.. (2025). A retrospective natural history study in adult and juvenile patients with incident dermatomyositis and polymyositis using real world data. Clinical Rheumatology. 44(10). 4237–4247. 1 indexed citations

Silverberg, Jonathan I., Robert S. Kirsner, David J. Margolis, et al.. (2024). Efficacy and safety of crisaborole ointment, 2%, in participants aged ≥45 years with stasis dermatitis: Results from a fully decentralized, randomized, proof-of-concept phase 2a study. Journal of the American Academy of Dermatology. 90(5). 945–952. 8 indexed citations

Silverberg, Jonathan I., Robert S. Kirsner, David J. Margolis, et al.. (2023). 42037 Phase 2a Study of Efficacy and Safety of Crisaborole in Patients with Stasis Dermatitis Using a Decentralized Evaluation Method. Journal of the American Academy of Dermatology. 89(3). AB207–AB207. 1 indexed citations

Fowler, Joseph F., Jeremy Sugarman, Lawrence Sher, et al.. (2023). Impact of Crisaborole on Sleep Outcomes in Pediatric Patients with Mild-to-Moderate Atopic Dermatitis. Dermatology and Therapy. 13(4). 951–960. 3 indexed citations

Bosch, Filip Van den, James Cheng‐Chung Wei, Peter Nash, et al.. (2022). Etanercept Withdrawal and Retreatment in Nonradiographic Axial Spondyloarthritis: Results of RE-EMBARK, an Open-Label Phase IV Trial. The Journal of Rheumatology. 50(4). 478–487. 3 indexed citations

Su, John, Lynda Spelman, Lawrence F. Eichenfield, et al.. (2021). Efficacy And Safety Of Crisaborole In Patients Aged 3 Months To 17 Years With Mild-To-Moderate Atopic Dermatitis. PEDIATRICS. 147(3_MeetingAbstract). 302–303.

Moriwaki, Shinichi, et al.. (2021). A phase 2b, randomized, double‐blind, multicenter, vehicle‐controlled study to assess the efficacy and safety of two crisaborole regimens in Japanese patients aged 2 years and older with mild‐to‐moderate atopic dermatitis. The Journal of Dermatology. 48(11). 1640–1651. 13 indexed citations

Giles, Jon T., Alexis Ogdie, Juan J. Gómez‐Reino, et al.. (2021). Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis. RMD Open. 7(1). e001486–e001486. 26 indexed citations

Mease, Philip J., Christina Charles‐Schoeman, Stanley Cohen, et al.. (2020). Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data. Annals of the Rheumatic Diseases. 79(11). 1400–1413. 153 indexed citations

10.

Bosch, Filip Van den, James Cheng‐Chung Wei, Francisco J. Blanco, et al.. (2020). Predictors of Maintaining Inactive Disease After Etanercept Withdrawal, and Regaining Inactive Disease Status After Flare and Retreatment, in Adults with Non-radiographic Axial Spondyloarthritis: Results from RE-EMBARK. Griffith Research Online (Griffith University, Queensland, Australia). 72. 4076–4078. 2 indexed citations

11.

Bosch, Filip Van den, Peter Nash, James Cheng‐Chung Wei, et al.. (2020). Efficacy Outcomes Following Etanercept Withdrawal by Sustained Remission Status in Patients with Nr-axSpA: Results from RE-EMBARK. Griffith Research Online (Griffith University, Queensland, Australia). 72. 2700–2703. 1 indexed citations

12.

Citera, Gustavo, Emilce E. Schneeberger, Peter Nash, et al.. (2019). Comparison of Different Remission Indices in Patients with Psoriatic Arthritis: A Post Hoc Analysis of Data from Phase 3 Tofacitinib Studies. Queensland's institutional digital repository (The University of Queensland). 26. 1 indexed citations

13.

Heijde, Désirée van der, Dafna D. Gladman, Oliver FitzGerald, et al.. (2019). Radiographic Progression According to Baseline C-reactive Protein Levels and Other Risk Factors in Psoriatic Arthritis Treated with Tofacitinib or Adalimumab. The Journal of Rheumatology. 46(9). 1089–1096. 39 indexed citations

14.

Nash, Peter, Maria Greenwald, Wei Yu, et al.. (2019). The Impact of Time Since First Diagnosis on the Efficacy and Safety of Tofacitinib in Patients with Active Psoriatic Arthritis. Queensland's institutional digital repository (The University of Queensland). 71. 1 indexed citations

15.

Strand, Vibeke, Kurt de Vlam, Philip J. Mease, et al.. (2019). Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs. RMD Open. 5(1). e000806–e000806. 55 indexed citations

16.

Rigby, William F. C., Gerd R Burmester, Oliver FitzGerald, et al.. (2019). AB0440 CHANGES IN KEY LABORATORY VALUES WITH TOFACITINIB 5 MG BID TREATMENT IN PATIENTS WITH PSORIATIC ARTHRITIS AND RHEUMATOID ARTHRITIS. Annals of the Rheumatic Diseases. 78. 1682–1683. 1 indexed citations

17.

Burmester, Gerd R, William F. C. Rigby, Ernest Choy, et al.. (2018). Changes in Lymphocytes and Lymphocyte Subsets in Tofacitinib-Treated Patients with Psoriatic Arthritis. Queensland's institutional digital repository (The University of Queensland). 70. 1 indexed citations

18.

Rigby, William F. C., Gerd R Burmester, Oliver FitzGerald, et al.. (2018). Changes in Key Laboratory Values with Tofacitinib 5mg BID Treatment in Patients with Psoriatic Arthritis and Rheumatoid Arthritis. Queensland's institutional digital repository (The University of Queensland). 70. 1 indexed citations

19.

Mahadevan, Uma, Marla C. Dubinsky, Chinyu Su, et al.. (2018). Outcomes of Pregnancies With Maternal/Paternal Exposure in the Tofacitinib Safety Databases for Ulcerative Colitis. Inflammatory Bowel Diseases. 24(12). 2494–2500. 124 indexed citations

20.

Mease, Philip J., Stephen Hall, Oliver FitzGerald, et al.. (2017). Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis. New England Journal of Medicine. 377(16). 1537–1550. 421 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact